

Type 1 Diabetes Management Before, During, and After Pregnancy

INTRODUCTION

Women with type 1 diabetes (T1D) have unique pregnancy-related needs.¹ Specifically, pregnancy planning and appropriate T1D management during pregnancy are critical to¹:

- Maintain lower hemoglobin A1c (HbA1c) and optimal blood glucose (BG) levels throughout pregnancy
- Reduce the risk of congenital malformations
- Achieve greater gestational age at delivery
- · Minimize the need for cesarean delivery
- Lower the risk of perinatal mortality

In addition, after delivery, women with T1D require careful readjustment of insulin doses, and contraception counseling is critical to prevent unplanned pregnancies.²

Consider the case of Justine, and think about how her current state of diabetes management could affect her health and the development and future health of her child:

- Justine is a 25-year-old G1PO woman who has had T1D for 14 years; one month ago, her HbA1c was 12.7%
- She presents for this endocrine visit at 11 weeks' gestation; she has high-risk proliferative diabetic retinopathy in both eyes, which was previously treated with scattered laser photocoagulation; her urine albumin-to-creatinine ratio (ACR) is 1428.0 mcg/mg, indicating diabetic nephropathy; she had been taking an angiotensin-converting enzyme inhibitor for hypertension, but she was switched to nifedipine
- · Her pregnancy was unplanned

This case illustrates troubling gaps in care. Justine's high HbA1c levels, insufficient treatment of comorbidities, and use of medications that are unsafe during pregnancy all increase her risk of maternal, fetal, and neonatal complications.

This handout highlights how healthcare providers can best address the special needs of their patients who are pregnant or planning to become pregnant to help ensure that they and their newborns have optimal outcomes, thereby avoiding situations such as Justine's.


T1D MANAGEMENT BEFORE PREGNANCY

Achieving glycemic targets is one of the primary goals of preconception care because HbA1c levels at conception affect pregnancy outcomes. Higher HbA1c levels during the first trimester are associated with an increased rate of congenital abnormalities. Birth defects can form as early as the

first 3 to 6 weeks after ovulation—before most women know they are pregnant—underscoring the importance of controlling BG levels before conceiving.³ In addition, HbA1c levels of 6.5% or higher during the first trimester are associated with a 4-fold increase in the risk of preeclampsia later in pregnancy.⁴

Recommendations for preconception care are summarized in Table 1.^{1,5,7} Importantly, prognostic information gathered during preconception planning can help guide T1D management during and after pregnancy.⁵ For example, the presence and extent of retinopathy at conception predicts the risk of progression, with severe forms more likely to deteriorate during and up to 1 year after pregnancy. Women with renal dysfunction at conception also have a higher risk of adverse pregnancy outcomes, including preeclampsia.⁵

TABLE 1. Preconception Care Checklist for Women with T1D



FACULTY

Florence Brown, MD

Co-Director
Joslin-Beth Israel Deaconess
Diabetes and Pregnancy
Program

Assistant Professor of Medicine Harvard Medical Boston, MA

WRITER

Anne Jacobson, MSPharm, CHCP, CPHQ Cocoa Beach, FL

ACTIVITY PLANNERS

Jaime Symowicz, PhD Manager, Educational Strategy and Content Med-IQ Baltimore. MD

Lisa R. Rinehart, MS, ELS Director, Editorial Services Med-IQ Baltimore, MD

Samantha Gordon CME Specialist Med-IQ Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM

Senior Manager, Accreditation and Compliance Med-IQ East Lansing, MI

This activity is funded in part by JDRF and The Leona M. and Harry B. Helmsley Charitable Trust and supported by an educational grant from Novo

© 2020 JDRF, Inc.

Developed in collaboration





TABLE 1. Preconception Care Checklist for Women with T1D (cont.)

ASSESS MEDICATIONS	☐ Safety for pregnancy ☐ Discontinue/switch classes as needed
SCREEN FOR RETINOPATHY	☐ Obtain ophthalmologist assessment of level of retinopathy and clearance to pursue pregnancy
ACHIEVE BP CONTROL	□ Target BP < 135/85 mm Hg □ Review BP medications; discuss stopping ACE inhibitors/ARBs
MANAGE NEPHROPATHY RISK	☐ Monitor BP, serum creatinine, and urine ACR
ASSESS THYROID FUNCTION	$\ \square$ Target preconception TSH \le 2.5 in patients with known hypothyroidism
ADDRESS RISK BEHAVIORS	☐ Smoking and alcohol use ☐ Referral for treatment of high-risk behaviors
REFER FOR DIABETES CARE	☐ Referral to diabetes pregnancy and specialty care team to support preconception planning and T1D management during pregnancy

T1D MANAGEMENT DURING PREGNANCY

Glycemic Targets

The maintenance of glycemic goals during pregnancy is important to reduce the risk of maternal and fetal complications.¹ High BG in the maternal circulatory system is shared with the fetal circulatory system, increasing the risk of excessive fetal growth and large-for-gestational-age (LGA) neonates.¹

Current guidelines from the American College of Obstetrics and Gynecology (ACOG) and American Diabetes Association (ADA) generally agree on glycemic targets for pregnant women with T1D (Table 2).^{6,7} Other groups support tighter goals for some targets, such as 1-hour post-meal BG (100 to 129 mg/dL).⁸

TABLE 2. Glycemic Targets During Pregnancy

HbA1c GOAL	< 6.0% without severe hypoglycemia
TIME IN RANGE	> 70% of time within 63 to 140 mg/dL
FASTING AND PRE-MEAL BG	60 to 95 mg/dL
1-HOUR POSTPRANDIAL BG	100 to 140 mg/dL

Role of Continuous Glucose Monitoring

Glycemic targets are difficult to maintain during pregnancy because of the complexity of insulin dosing, pregnancy-related changes in insulin sensitivity, and pronounced swings in insulin absorption during late pregnancy. In one study, only 14.3% of women with T1D had HbA1c levels lower than 6.5% during early pregnancy, and only 40% were at target by 24 weeks' gestation.

Continuous glucose monitoring (CGM) systems can measure glucose up to 300 times per day, alert users to glucose highs or lows, and display information on glucose trends, enabling patients to respond to changes as they occur. In the CONCEPTT study of CGM use in pregnant women with T1D, CGM users spent more time at target and less time in hyperglycemic ranges than women using capillary glucose monitoring alone. Neonatal outcomes were also better with CGM use during pregnancy—including a lower rate of LGA neonates, fewer neonatal hypoglycemic episodes, fewer intensive care admissions lasting more than 24 hours, and shorter hospital stays—likely due to lower exposure to maternal hyperglycemia.

Despite achieving glycemic goals, however, the risk of excessive fetal growth remains high in pregnancies complicated by T1D.¹² In another study of pregnant women with T1D, CGM use was associated with having mean HbA1c levels of 6.5%, 6.1%, and 6.4% across the first, second, and third trimesters, respectively—yet 63% of neonates in the study were classified as LGA, and the mean birthweight exceeded 4,000 g.¹²

Every tool available is important for maintaining optimal glycemic targets during pregnancy. Even when CGM is being used to monitor glucose trends, patients should test fasting and post-meal BG levels and adjust basal and bolus insulin doses as needed. Furthermore, many CGM devices require calibration with capillary glucose test results 2 to 4 times per day.¹¹

Optimal Insulin Delivery

In those with T1D, insulin requirements change throughout pregnancy, with distinct cumulative peaks and troughs (Table 3).¹³ Daily insulin requirements will nearly double by 36 weeks' gestation relative to pre-pregnancy requirements. Frequent and close monitoring with healthcare providers is essential, and understanding these normal patterns is helpful to react to changes in prompt and effective ways.¹³

New technologies that incorporate CGM with insulin delivery systems are now emerging. These automated systems—known as sensor-integrated insulin delivery, closed-loop insulin delivery, and the artificial pancreas—analyze real-time glucose measurements from the CGM to calculate the amount of insulin to deliver via subcutaneous infusion pumps. In a study of pregnant women with T1D, closed-loop insulin delivery

TABLE 3. Changes in Insulin Requirements During Pregnancy

	CHANGE PER PERIOD		
	Insulin Dose Requirement (U/kg per day)	Total Insulin Requirement (U/day)	
First 9 weeks	1 9.1%	1 2.1%	
9 to 15 weeks	↓ 14.3%	↓ 10.9%	
16 to 36 weeks	↑ 71.5%	1 94.6%	

Data derived from García-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. *Diabetologia*. 2010;53(3):446-451.

improved the proportion of time that BG was within target range by 15.2% compared with standard pump therapy, without an increase in hypoglycemia.¹⁴

Hypertension and Comorbidity Management

As with preconception planning (see Table 1), careful attention to hypertension, retinopathy, nephropathy, and other comorbidities and complications should be continued throughout pregnancy. Antihypertensive and other medications should be confirmed to be safe for use during pregnancy.²

Optimal Nutrition

Proper nutrition is important during preconception care and pregnancy. A subgroup analysis of CONCEPTT showed that pregnant women with T1D had higher-than-recommended intakes of fat and inadequate intakes of fiber, fruit, and vegetables. Although their carbohydrate intake of 180 to 200 g/day was consistent with guideline recommendations, approximately 50% of this intake was derived from non-recommended, high-glycemic sources (eg, sugary/savory snacks, non-alcoholic beverages), which does not align with guideline recommendations and underscores the need for pre- and post-conception medical nutrition therapy. 15-17 Although more research is needed to identify optimal nutrition for pregnant women with T1D, a randomized controlled pilot study of women with gestational diabetes reported that a higher-complex-carbohydrate/lower-fat diet was associated with improved maternal insulin resistance and infant adiposity compared with a low-carbohydrate/higher-fat diet. 18

T1D MANAGEMENT AFTER PREGNANCY

Specialized diabetes care should continue into the postpartum period, when women with T1D can experience a substantial decrease of up to 50% of pre-pregnancy insulin requirements.² Breastfeeding also contributes to increased insulin sensitivity and the need to adjust insulin dosing. Long-acting reversible contraception should be considered in the immediate post-partum period, before women develop barriers to contraception access.²

MPORTANT

Women experience postpartum changes in insulin sensitivity:

- Insulin requirements may fall to as low as 50% of preconception needs
- Insulin doses need to be titrated upwards to preconception doses
- Breastfeeding can increase insulin sensitivity

CASE DISCUSSION

Let's look back on Justine's case. If you were her healthcare provider, what important points would you discuss with her when she returns for a follow-up visit after giving birth?

- ✓ Birth control—it will be imperative to make sure Justine understands the importance of avoiding another unplanned pregnancy until reaching her glycemic goals
- ✓ Preconception care—if Justine is considering having another child in the future, it will be important to discuss how you will work with her to achieve her glycemic targets and address her diabetes-related complications before becoming pregnant to reduce fetal, neonatal, and maternal risks

PATIENT EDUCATION RESOURCES



We hope that you found this to be a helpful overview of T1D management before, during, and after pregnancy. The following resource provides additional patient education for women with T1D who are pregnant or planning to become pregnant: www.jdrf.org/t1d-resources/living-with-t1d/pregnancy/.

REFERENCES

- 1. Feldman AZ, Brown FM. Management of type 1 diabetes in pregnancy. Curr Diab Rep. 2016;16(8):76-89.
- 2. Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. *JAMA*. 2019;321(18):1811-1819.
- 3. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. *Diabetes Care*. 2007;30(7):1920-1925.
- 4. Cohen AL, Wenger JB, James-Todd T, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. *Hypertens Pregnancy*. 2014;33(1):81-92.
- 5. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2013;98(11):4227-4249.
- American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 201: pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248.
- 7. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S183-S192.
- 8. Joslin Diabetes Center and Joslin Clinic. Guideline for detection and management of diabetes in pregnancy. Corrected January 11, 2017. www.joslin.org/media/28/download. Accessed October 30, 2019.
- 9. Feig DS, Donovan LE, Corcoy R, et al; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet*. 2017;390(10110):2347-2359.
- 10. Murphy HR, Bell R, Cartwright C, et al. Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. *Diabetologia*. 2017;60(9):1668-1677.
- 11. Yamamoto JM, Murphy HR. Emerging technologies for the management of type 1 diabetes in pregnancy. *Curr Diab Rep.* 2018;18(1):4-13.
- 12. Mulla BM, Noor N, James-Todd T, et al. Continuous glucose monitoring, glycemic variability, and excessive fetal growth in pregnancies complicated by type 1 diabetes. *Diabetes Technol Ther.* 2018;20(6):413-419.
- 13. García-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. *Diabetologia*. 2010;53(3):446-451.
- 14. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med. 2016;375(7):644-654.
- 15. Neoh SL, Grisoni JA, Feig DR, Murphy HR; CONCEPTT Collaborative Group. Dietary intakes of women with type 1 diabetes before and during pregnancy: a pre-specified secondary subgroup analysis among CONCEPTT participants. *Diabet Med.* 2019;Feb 20. [Epub ahead of print]
- 16. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. *Diabetes Care*. 2008;31(5):1060-1079.
- 17. Duarte-Gardea MO, Gonzalezs-Pacheco DM, Reader DM, et al. Academy of Nutrition and Dietetics gestational diabetes evidence-based nutrition practice guideline. *J Acad Nutr Diet*. 2018;118(9):1719-1742.
- 18. Hernandez TL, Van Pelt RE, Anderson MA, et al. Women with gestational diabetes mellitus randomized to a higher-complex carbohydrate/low-fat diet manifest lower adipose tissue insulin resistance, inflammation, glucose, and free fatty acids: a pilot study. *Diabetes Care*. 2016;39(1):39-42.